Harvard Apparatus Regenerative Technology (HRGN) Stock Overview

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, engages in developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma, or birth defects. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. Harvard Apparatus Regenerative Technology Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.